BioCentury
ARTICLE | Clinical News

Canagliflozin regulatory update

July 2, 2012 7:00 AM UTC

Johnson & Johnson submitted an MAA to EMA for canagliflozin to treat Type II diabetes. In May, J&J submitted an NDA to FDA for the once-daily oral sodium-glucose transporter 2 ( SGLT2) inhibitor. J&J ...